Lymphoma

Latest News

The FDA originally placed a clinical hold on the program for tab-cel in January 2025 due to Good Manufacturing Practice (GMP) compliance issues associated with a pre-license inspection of a third-party manufacturing facility.

FDA Lifts Clinical Hold on Tabelecleucel in EBV+ Lymphoproliferative Disease

May 7th 2025

Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related posttransplant lymphoproliferative disease.

Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.

Acalabrutinib Combo Receives EU Approval for Mantle Cell Lymphoma

By Roman Fabbricatore

May 6th 2025

CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

By Tim Cortese

April 25th 2025

Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Large B-Cell Lymphoma

By American Society for Transplantation and Cellular Therapy

April 24th 2025

Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

Elucidating the Clinical Landscape for Rare Lymphoma Treatment

By Roman Fabbricatore

April 17th 2025

Latest CME Events & Activities

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

...

56 57 58 59 60

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777